Welcome to our dedicated page for Alpha Teknova news (Ticker: TKNO), a resource for investors and traders seeking the latest updates and insights on Alpha Teknova stock.
Alpha Teknova, Inc. (Nasdaq: TKNO) is a prominent player in the life sciences industry, providing essential reagents that propel the discovery, development, and commercialization of biopharmaceutical products. Founded in 1996 and headquartered in Hollister, California, Teknova specializes in producing high-quality, customizable media, buffers, and reagents designed to support bacterial and yeast applications.
Teknova’s comprehensive product portfolio includes pre-poured media plates for cell growth and cloning, liquid cell culture media for cellular expansion, and molecular biology reagents for sample manipulation, resuspension, and purification. The company is renowned for its proprietary soluble pouches, which offer dry microbiological media solutions in convenient, easy-to-use formats.
The company's latest achievements include the opening of a state-of-the-art manufacturing facility in Hollister, California. This new facility, spanning over 10,000 square feet, is GMP-certified under ISO 13485:2016, significantly enhancing Teknova’s capacity to produce high-quality reagents for bioprocessing and gene therapy companies. This facility represents a three-fold increase in Teknova’s overall manufacturing capacity and reinforces its commitment to supporting customers through all stages of their clinical lifecycle.
Recent financial results show a strong performance, with the company reporting sequential revenue growth of 26% for the second quarter of 2023, despite facing market challenges. Teknova's strategic initiatives, such as the launch of the Build-Tek Solutions custom product configurator and the AAV-Tek AEX Buffer Screening Kit, underscore its dedication to innovation and customer-centric solutions.
Teknova derives most of its revenue from the United States and continues to expand its market presence through partnerships and product development. The company's modular manufacturing platform, designed by a team of scientists, engineers, and quality control experts, ensures the efficient production of reagents vital for accelerating scientific breakthroughs.
For more information or to schedule a tour of Teknova’s new GMP-certified facility, visit their website.
Teknova (Nasdaq: TKNO) announced it will report Q1 financial results for the period ending March 31, 2023, on May 10, 2023, after market close. A conference call and webcast will follow at 5:00 p.m. ET on the same day, accessible via the company's Investor Relations page. Founded in 1996 and headquartered in Hollister, California, Teknova specializes in producing critical reagents for life sciences, supporting cell and gene therapy, molecular diagnostics, and synthetic biology. The company offers customizable solutions for various workflows, emphasizing fast turnaround of high-quality products, which are vital for therapy discovery and development.
FAQ
What is the current stock price of Alpha Teknova (TKNO)?
What is the market cap of Alpha Teknova (TKNO)?
What does Alpha Teknova, Inc. specialize in?
Where is Alpha Teknova, Inc. headquartered?
What recent facility development has Teknova announced?
What is Teknova's proprietary product line for gene therapy?
How did Teknova perform financially in the second quarter of 2023?
What are Teknova's main product categories?
What is the Build-Tek Solutions custom product configurator?
What is the significance of Teknova's modular manufacturing platform?
How does Teknova support biopharmaceutical companies?
What industries does Teknova serve?
